Assessing Prognosis: Factors Influencing Outcomes in Hospitalized Lung Cancer DOI Creative Commons
J. Peña, L. Gutierrez-Sainz, Diego Jiménez-Bou

et al.

Onco, Journal Year: 2024, Volume and Issue: 4(4), P. 458 - 470

Published: Dec. 19, 2024

Background: Patients with lung cancer experience higher rates of hospitalization due to their elevated mortality and associated comorbidities. Hospital admissions among oncology patients often indicate organ vulnerability are linked poor prognosis. This study aimed assess the characteristics potential prognostic factors hospitalized patients. Methods: We retrospectively analyzed 646 admitted from June 2021 May 2022 Medical Oncology Service at La Paz University (Madrid, Spain). Results: During this period, 158 had (24.5%). The median overall survival since admission (mOSSA) was 3.3 months (95%CI: 1.86–7.74). In univariate analysis, poorer mOSSA for tumor-related causes (1.33 vs. 7.30 months, p < 0.001), ECOG ≥ 2 (2.43 8.50 NLR 6 (1.87 7.40 months), PNI ≤ 40 (1.67 4.97 LDH 210 (2.27 7.87 = 0.044). multivariate independent included (p 0.032, aHR 1.81, 95%CI: 1.05–3.11) 0.041, 1.80, 1.03–3.16). Conclusions: is a event, particularly when or decline in performance status.

Language: Английский

Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung Cancer DOI Open Access
Nicoletta Cordani,

Daniele Nova,

Luca Sala

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(20), P. 11214 - 11214

Published: Oct. 18, 2024

Non-small cell lung cancer (NSCLC) remains a disease with poor prognosis despite the advances in therapies. NSCLC actionable oncogenic alterations represent subgroup of diseases for which tyrosine kinase inhibitors (TKIs) have shown relevant and robust impact on prognosis, both early advanced stages. While introduction powerful TKIs increases ratio potentially curable patients, does develop resistance over time through either secondary mutations or bypass activating tracks. Therefore, new treatment strategies are being developed to overcome this inevitable prevent it, proteolysis targeting chimera agents (PROTACs) among them. They consist two linked molecules that bind target protein an E3 ubiquitin ligase causes ubiquitination degradation proteins interest. In paper, we review rationale PROTAC therapy current development PROTACs oncogene-addicted cancer. Moreover, critically analyze strengths limitations promising technique may help pave way future perspectives.

Language: Английский

Citations

0
Prognostic Role of Inflammatory and Nutritional Biomarkers in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors Alone or in Combination with Chemotherapy as First-Line DOI Open Access
Antonello Veccia,

Mariachiara Dipasquale,

Stefania Kinspergher

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(22), P. 3871 - 3871

Published: Nov. 19, 2024

In recent years, several inflammation-related factors and nutritional parameters have been evaluated to develop prognostic scores as potential biomarkers in non-small-cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors (ICIs). The aim of this study was retrospectively investigate the role advanced inflammation (ALI) index, index (LIPI), (PNI) systemic score (SIS) metastatic NSCLC ICI alone or combination with chemotherapy.

Language: Английский

Citations

0
Durvalumab, tremelimumab and platinum chemotherapy in EGFR mutation positive non-small cell lung cancer - an open label phase 2 trial (ILLUMINATE) DOI Creative Commons
Chee Khoon Lee, Bin-Chi Liao, Shalini Subramaniam

et al.

JTO Clinical and Research Reports, Journal Year: 2024, Volume and Issue: 6(2), P. 100771 - 100771

Published: Nov. 22, 2024

Language: Английский

Citations

0
Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC DOI Creative Commons

Michelle Shiller,

Melissa L. Johnson, Robert P. Auber

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Dec. 5, 2024

Standard first-line therapy for patients with metastatic non-small cell lung cancer (mNSCLC) without identified actionable mutations consists of regimens comprising immune checkpoint inhibitors (ICIs), alone or in combination platinum-based chemotherapy (CTx). However, approximately 20-30% mNSCLC (including some high tumor programmed death ligand-1 expression) display primary resistance to ICIs, either CTx. Mutations suppressor genes

Language: Английский

Citations

0
Assessing Prognosis: Factors Influencing Outcomes in Hospitalized Lung Cancer DOI Creative Commons
J. Peña, L. Gutierrez-Sainz, Diego Jiménez-Bou

et al.

Onco, Journal Year: 2024, Volume and Issue: 4(4), P. 458 - 470

Published: Dec. 19, 2024

Background: Patients with lung cancer experience higher rates of hospitalization due to their elevated mortality and associated comorbidities. Hospital admissions among oncology patients often indicate organ vulnerability are linked poor prognosis. This study aimed assess the characteristics potential prognostic factors hospitalized patients. Methods: We retrospectively analyzed 646 admitted from June 2021 May 2022 Medical Oncology Service at La Paz University (Madrid, Spain). Results: During this period, 158 had (24.5%). The median overall survival since admission (mOSSA) was 3.3 months (95%CI: 1.86–7.74). In univariate analysis, poorer mOSSA for tumor-related causes (1.33 vs. 7.30 months, p < 0.001), ECOG ≥ 2 (2.43 8.50 NLR 6 (1.87 7.40 months), PNI ≤ 40 (1.67 4.97 LDH 210 (2.27 7.87 = 0.044). multivariate independent included (p 0.032, aHR 1.81, 95%CI: 1.05–3.11) 0.041, 1.80, 1.03–3.16). Conclusions: is a event, particularly when or decline in performance status.

Language: Английский

Citations

0